Contribution of DNA and Tissue Microarray Technology to the Identification and Validation of Biomarkers and Personalised Medicine in Breast Cancer
作者： Elton Rexhepaj , William M. Gallagher , Donal J. Brennan , Catherine Kelly , Peter A. Dervan
DOI:
关键词:
摘要: Completion of the human genome project has revolutionised translational medicine. High-throughput technology now permits investigators to systematically interrogate genome, transcriptome, proteome and metabolome. It is expected that these advances will eventually be translated into new more sensitive diagnostic tests less toxic therapeutics. A major shift in clinical oncology over next few decades as we start move away from currently practiced, population-based approaches personalised In this emerging approach, molecular pathophysiological characteristics an individual patient tumour measured tailored therapeutic regimens administered based on profiles. One key steps process identification validation biomarkers. Whilst great have been made discovery putative biomarkers, disappointingly clinically applicable assays. widely believed due a lack well-designed, thorough studies. Here, review role DNA microarrays tissue biomarkers breast cancer, with emphasis their potential application determine mode therapy future.
参考文章(82)
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework* Clinical Pharmacology & Therapeutics. ,vol. 69, pp. 89- 95 ,(2001) , 10.1067/MCP.2001.113989
Teresa W M Fan, Andrew N Lane, Richard M Higashi, The promise of metabolomics in cancer molecular therapeutics. Current Opinion in Molecular Therapeutics. ,vol. 6, pp. 584- 592 ,(2004)
Stephen M. Hewitt, [20] The Application of Tissue Microarrays in the Validation of Microarray Results Methods in Enzymology. ,vol. 410, pp. 400- 415 ,(2006) , 10.1016/S0076-6879(06)10020-8
Carlos Caldas, Samuel A. J. Aparicio, Cancer: The molecular outlook Nature. ,vol. 415, pp. 484- 485 ,(2002) , 10.1038/415484A
Tamoxifen for early breast cancer: An overview of the randomised trials The Lancet. ,vol. 351, pp. 1451- 1467 ,(1998) , 10.1016/S0140-6736(97)11423-4
Lajos Pusztai, Mark Ayers, James Stec, Edward Clark, Kenneth Hess, David Stivers, Andrew Damokosh, Nour Sneige, Thomas A Buchholz, Francisco J Esteva, Banu Arun, Massimo Cristofanilli, Daniel Booser, Marguerite Rosales, Vicente Valero, Constantine Adams, Gabriel N Hortobagyi, W Fraser Symmans, None, Gene Expression Profiles Obtained from Fine-Needle Aspirations of Breast Cancer Reliably Identify Routine Prognostic Markers and Reveal Large-Scale Molecular Differences between Estrogen-negative and Estrogen-positive Tumors Clinical Cancer Research. ,vol. 9, pp. 2406- 2415 ,(2003)
Catherine M Conway, Deirdre O'Shea, Sallyann O'Brien, Darragh K Lawler, Graham D Dodrill, Anthony O'Grady, Helen Barrett, Christian Gulmann, Lorraine O'Driscoll, William M Gallagher, Elaine W Kay, Daniel G O'Shea, The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line BMC Bioinformatics. ,vol. 7, pp. 256- 256 ,(2006) , 10.1186/1471-2105-7-256
Stephen K. Chia, Charles C. Wykoff, Peter H. Watson, Cheng Han, Russell D. Leek, Jaromir Pastorek, Kevin C. Gatter, Peter Ratcliffe, Adrian L. Harris, Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma Journal of Clinical Oncology. ,vol. 19, pp. 3660- 3668 ,(2001) , 10.1200/JCO.2001.19.16.3660
Bernard Fisher, Joseph Costantino, Carol Redmond, Roger Poisson, David Bowman, Jean Couture, Nikolay V Dimitrov, Norman Wolmark, D Lawrence Wickerham, Edwin R Fisher, Richard Margolese, Andre Robidoux, Henry Shibata, Jose Terz, AHG Paterson, Merrill I Feldman, William Farrar, James Evans, H Lavina Lickley, Mary Ketner, *, None, A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors New England Journal of Medicine. ,vol. 320, pp. 479- 484 ,(1989) , 10.1056/NEJM198902233200802
Anupama E. Gururaj, Caroline Holm, Göran Landberg, Rakesh Kumar, Breast cancer-amplified sequence 3, a target of metastasis-associated protein 1, contributes to tamoxifen resistance in premenopausal patients with breast cancer. Cell Cycle. ,vol. 5, pp. 1407- 1410 ,(2006) , 10.4161/CC.5.13.2924